Results 231 to 240 of about 31,601 (273)

Will the emerging private-label market access channel help or hinder biosimilar market access? [PDF]

J Manag Care Spec Pharm
Mehr SR.
europepmc   +1 more source

Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry. [PDF]

Gastro Hep Adv
Oketola B, Bernatsky S, Lukusa L, Moura CS, Neville A, Leung Y, Narula N, Afif W, Birck MG, Zezos P, Singh H, Canadian IBD Research Consortium.   +11 more
europepmc   +1 more source

Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer. [PDF]

Breast Cancer Res Treat
Alonso-Romero JL, Martínez-García J, Carrillo-Vicente R, Aramburo AF, Díez AF, Henarejos PS, de la Morena Barrio P, Boix AP, Jiménez MD, Siles JP, Maestre JAP, de Las Heras-Rubio A, Carreño PR.   +12 more
europepmc   +1 more source

Oral delivery of an ustekinumab biosimilar with bioavailability comparable to subcutaneous administration in healthy human participants. [PDF]

Eur J Clin Pharmacol
Myers JT, Yamaguchi A, Horlen K, Fung LC, Vo AT, Mohan D, Hoopes M, Imran M, Van Dam J, Gonen OM, Hashim MA, Dhalla AK, Blauvelt A.   +12 more
europepmc   +1 more source

Recent changes in discretionary denials of drug patent challenges. [PDF]

Health Aff Sch
Tu SS, Rai A, Kesselheim AS.
europepmc   +1 more source

LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis. [PDF]

J Endocr Soc
Krecipro-Nizinska E, Pluskiewicz W, Supronik J, Szeles P, Petit-Frere C, Varone E, Ferrari S, Valter I.   +7 more
europepmc   +1 more source

Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. [PDF]

Psoriasis (Auckl)
Gisondi P, Bellinato F, Curic T, Girolomoni G.   +3 more
europepmc   +1 more source

Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028. [PDF]

J Manag Care Spec Pharm
Cousin EM, Martin K, Hansen RN, Coster J, Sullivan SD.   +4 more
europepmc   +1 more source

Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: a multicenter cross-sectional study in Catalonia, Spain. [PDF]

Clin Rheumatol
Mas Marin J, Molina-Olano M, Sola NR, Miserachs-Aranda N, Montoliu Alcón P, De Pourcq JT, Quiñones Ribas C, Borràs Trias L, Fernández-Cañabate E, González-Valdivieso J, Figueiredo-Escribá C, Delgado-Hernández R, Braza AJ, Lastra CF, Mariño EL, Modamio P.   +15 more
europepmc   +1 more source